Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2014-05-21 12:48 |
WILEX AG: WILEX returns rights from collaboration in oncology to UCB and UCB wa…
|
English | 4.7 KB | ||
| 2014-04-30 12:32 |
WILEX AG: WILEX and IBA terminate marketing partnership - Global rights to REDE…
|
English | 5.9 KB | ||
| 2014-04-14 15:16 |
Wilex AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.05.2014 in …
|
German | 42.6 KB | ||
| 2014-04-14 07:05 |
WILEX AG publishes 3-month Financial Report 2014
|
English | 24.5 KB | ||
| 2014-04-14 00:00 |
Q1 Report 2013/2014
|
German | 1.0 MB | ||
| 2014-04-10 13:32 |
WILEX AG plans reduction of share capital
|
English | 5.5 KB | ||
| 2014-03-31 07:15 |
WILEX AG: WILEX announces financial figures for the 2013 financial year and rep…
|
English | 30.6 KB | ||
| 2014-03-31 00:00 |
Annual Financial Statements 2012/2013
|
English | 3.5 MB | ||
| 2014-03-28 17:25 |
WILEX AG: WILEX enters into licensing and development partnership for MESUPRON(…
|
English | 12.0 KB | ||
| 2014-03-28 17:18 |
WILEX AG: WILEX enters into licensing and development partnership for MESUPRON(…
|
English | 6.1 KB | ||
| 2014-03-28 15:06 | English | 2.6 KB | |||
| 2014-03-25 14:11 |
WILEX AG: WILEX will publish the financial results and the Annual Report 2013 o…
|
English | 5.9 KB | ||
| 2014-02-24 21:50 |
WILEX AG: Professor Olaf G. Wilhelm leaves the Executive Management Board on 31…
|
English | 8.7 KB | ||
| 2014-02-24 21:46 |
WILEX AG: Professor Olaf G. Wilhelm leaves the Executive Management Board on 31…
|
English | 5.4 KB | ||
| 2014-01-29 17:01 |
WILEX AG plans extensive cost-cutting measures
|
English | 11.0 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
Peer Companies
